Sanofi SA Valuation
| SAN Stock | EUR 90.87 0.07 0.08% |
At this time, the company appears to be undervalued. Sanofi SA has a current Real Value of €94.58 per share. The regular price of the company is €90.87. Our model measures the value of Sanofi SA from inspecting the company fundamentals such as Shares Outstanding of 1.25 B, return on equity of 0.12, and Operating Margin of 0.24 % as well as reviewing its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Sanofi SA's price fluctuation is very steady at this time. Calculation of the real value of Sanofi SA is based on 3 months time horizon. Increasing Sanofi SA's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sanofi SA is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sanofi Stock. However, Sanofi SA's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 90.87 | Real 94.58 | Hype 90.87 | Naive 89.83 |
The real value of Sanofi Stock, also known as its intrinsic value, is the underlying worth of Sanofi SA Company, which is reflected in its stock price. It is based on Sanofi SA's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Sanofi SA's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Sanofi SA helps investors to forecast how Sanofi stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sanofi SA more accurately as focusing exclusively on Sanofi SA's fundamentals will not take into account other important factors: Sanofi SA Total Value Analysis
Sanofi SA is at this time estimated to have takeover price of 128.44 B with market capitalization of 110.83 B, debt of 14.86 B, and cash on hands of 9.72 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Sanofi SA fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
128.44 B | 110.83 B | 14.86 B | 9.72 B |
Sanofi SA Investor Information
About 47.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.61. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sanofi SA has Price/Earnings To Growth (PEG) ratio of 1.63. The entity recorded earning per share (EPS) of 6.66. The firm last dividend was issued on the 6th of May 2022. Sanofi SA had 4:1 split on the 24th of May 1999. Based on the key measurements obtained from Sanofi SA's financial statements, Sanofi SA is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Sanofi SA Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sanofi SA has an asset utilization ratio of 36.43 percent. This suggests that the Company is making €0.36 for each dollar of assets. An increasing asset utilization means that Sanofi SA is more efficient with each dollar of assets it utilizes for everyday operations.Sanofi SA Ownership Allocation
Sanofi SA shows a total of 1.25 Billion outstanding shares. 30% of Sanofi SA outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Sanofi SA Profitability Analysis
The company reported the revenue of 45.39 B. Net Income was 8.37 B with profit before overhead, payroll, taxes, and interest of 31.7 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Sanofi SA's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Sanofi SA and how it compares across the competition.
About Sanofi SA Valuation
The stock valuation mechanism determines Sanofi SA's current worth on a weekly basis. Our valuation model uses a comparative analysis of Sanofi SA. We calculate exposure to Sanofi SA's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sanofi SA's related companies.Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. Sanofi was incorporated in 1994 and is headquartered in Paris, France. SANOFI operates under Drug ManufacturersGeneral classification in France and is traded on Paris Stock Exchange. It employs 99412 people.
8 Steps to conduct Sanofi SA's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Sanofi SA's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Sanofi SA's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Sanofi SA's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Sanofi SA's revenue streams: Identify Sanofi SA's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Sanofi SA's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Sanofi SA's growth potential: Evaluate Sanofi SA's management, business model, and growth potential.
- Determine Sanofi SA's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Sanofi SA's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Sanofi Stock analysis
When running Sanofi SA's price analysis, check to measure Sanofi SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi SA is operating at the current time. Most of Sanofi SA's value examination focuses on studying past and present price action to predict the probability of Sanofi SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi SA's price. Additionally, you may evaluate how the addition of Sanofi SA to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |